Healthcare · Drug Manufacturers - General
Price
$0.09
Market Cap
$3.1M
Employees
11
Beta
0.74
Avg Volume
50,412,757
CEO
Kent Cunningham
Business Description
SRx Health Solutions Inc. functions as a unified Canadian enterprise providing healthcare services, specifically within the specialized medical sector. The company furnishes a complete range of personalized and interconnected specialty healthcare solutions throughout all ten provinces of Canada. Leveraging its deep industry insight, cutting-edge technology, and a patient-first approach, SRx devises strategic programs and services intended to markedly enhance the health and well-being of individuals across the nation.
Business History
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-0.04
Stock Price: $0.09
EPS (Diluted): -2.13
EPS (Diluted): -2.13
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
16.44
Stock Price: $0.09
Total Equity: $407,000
Shares: 21,107,043
Total Equity: $407,000
Shares: 21,107,043
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-1.23
Market Cap: $3.09M
Total Debt: $4.47M
Cash: $1.31M
EBITDA: -$11.50M
Total Debt: $4.47M
Cash: $1.31M
EBITDA: -$11.50M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$9.9M
Market Cap: $3.09M
Total Debt: $4.47M
Cash: $1.31M
Total Debt: $4.47M
Cash: $1.31M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
1.02
Stock Price: $0.09
Revenue: $6.53M
Shares: 21,107,043
Revenue: $6.53M
Shares: 21,107,043
EV/Sales (Total value vs revenue — works when P/E can't)
API1.51
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
23.4%
Gross Profit: $1.50M
Revenue: $6.53M
Revenue: $6.53M
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-174.6%
Operating Income: -$11.53M
Revenue: $6.53M
Revenue: $6.53M
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-688.8%
Net Income: -$45.01M
Revenue: $6.53M
Revenue: $6.53M
ROE (Profit from shareholder equity)
CALCNet Income / Total Equity
-11,058.0%
Net Income: -$45.01M
Total Equity: $407,000
Total Equity: $407,000
ROIC (Profit from all invested capital)
CALCNOPAT / Invested Capital
-322.9%
Operating Income: -$11.53M
Tax Rate: 0.0%
Equity: $407,000
Total Debt: $4.47M
Cash: $1.31M
Tax Rate: 0.0%
Equity: $407,000
Total Debt: $4.47M
Cash: $1.31M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
2.29
Current Assets: $8.13M
Current Liabilities: $3.54M
Current Liabilities: $3.54M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
10.99
Short-Term Debt: $21,000
Long-Term Debt: $4.45M
Total Debt: $4.47M
Total Equity: $407,000
Long-Term Debt: $4.45M
Total Debt: $4.47M
Total Equity: $407,000
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$0.31
Revenue: $6.53M
Shares: 21,107,043
Shares: 21,107,043
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$0.02
Total Equity: $407,000
Shares: 21,107,043
Shares: 21,107,043
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-0.39
Operating CF: -$8.14M
CapEx: $0.00
Shares: 21,107,043
CapEx: $0.00
Shares: 21,107,043
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $0.09
Stock Price: $0.09
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$45.01M
Net Income: -$45.01M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares SRXH against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 22, 2026 1:41am (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $58.6M | $92.6M | $118.9M | $50.3M | $6.5M |
| Cost of Revenue | $41.2M | $79.3M | $95.3M | $31.8M | $5.0M |
| Gross Profit | $17.5M | $13.3M | $23.6M | $18.5M | $1.5M |
| Operating Expenses | $39.5M | $14.5M | $29.4M | $27.1M | $13.0M |
| Operating Income | -$22.0M | -$1.2M | -$5.8M | -$8.6M | -$11.5M |
| Net Income | $3.8M | -$2.4M | -$11.1M | $-241,599 | -$45.0M |
| EBITDA | $10.6M | $-539,401 | -$7.1M | $629,883 | -$11.5M |
| EPS | $8.40 | $-3.48 | $-0.90 | $-0.14 | $-2.13 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 22, 2026 1:41am (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $36.9M | $1.7M | $2.1M | $4.7M | $1.3M |
| Total Current Assets | $56.0M | $14.8M | $25.1M | $20.4M | $8.1M |
| Total Assets | $98.7M | $34.8M | $64.5M | $21.4M | $8.4M |
| Current Liabilities | $9.4M | $22.0M | $65.5M | $81.3M | $3.5M |
| Long-Term Debt | $12.0M | $9.0M | $0 | $944,541 | $4.5M |
| Total Liabilities | $24.9M | $33.9M | $70.8M | $88.9M | $8.0M |
| Total Equity | $73.8M | $927,481 | -$6.3M | $10.3M | $407,000 |
| Retained Earnings | -$330.4M | -$6.3M | -$17.6M | -$95.0M | -$22.9M |
Cash Flow (Annual)
Last updated: Jun 23, 2026 8:39am (4d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$15.1M | -$27.6M | $2.8M | -$5.9M | -$8.1M |
| Capital Expenditure | $-449,892 | $-244,721 | -$1.3M | $-55,641 | $0 |
| Free Cash Flow | -$15.6M | $3.1M | $1.6M | -$6.0M | -$8.1M |
| Acquisitions (net) | $0 | -$5.7M | -$13.2M | -$3.2M | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | -$2.0M | $0 | $0 | $-279,563 | $-137,000 |
| Net Change in Cash | $31.8M | -$26.2M | $519,000 | -$1.9M | -$1.8M |
Analyst Estimates (Annual)
Last updated: Jun 26, 2026 8:09pm (12h ago)| Metric | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| Revenue |
$270.2M $270.2M – $270.2M
|
$348.7M $348.7M – $348.7M
|
$132.5M $132.5M – $132.5M
|
$152.3M $152.3M – $152.3M
|
| EBITDA |
-$47.1M -$47.1M – -$47.1M
|
-$60.8M -$60.8M – -$60.8M
|
-$23.1M -$23.1M – -$23.1M
|
-$26.6M -$26.6M – -$26.6M
|
| Net Income |
-$188.2M -$188.2M – -$188.2M
|
$336.8M $336.8M – $336.8M
|
$38.9M $38.9M – $38.9M
|
$284.9M $284.9M – $284.9M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 22, 2026 1:41am (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +58.0% | +28.4% | -57.7% | -87.0% |
| Gross Profit Growth | -23.8% | +77.5% | -21.7% | -91.9% |
| Operating Income Growth | +94.7% | -397.9% | -47.8% | -34.4% |
| Net Income Growth | -164.4% | -354.7% | +97.8% | -18,528.4% |
| EBITDA Growth | -105.1% | -1,207.3% | +108.9% | -1,925.6% |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for SRXH — it's generated by the pipeline (
market-narrative step).
No community reviews yet for SRXH.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30